DARÉ BIOSCIENCE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.36 USD | +14.29% |
|
+17.23% | +16.50% |
| 05-15 | Brookline Capital Upgrades Dare Bioscience to Buy From Hold, Price Target is $3 | MT |
| 05-14 | Transcript : Daré Bioscience, Inc., Q1 2024 Earnings Call, May 14, 2024 |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the Daré Bioscien...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.315
USD
Average target price
4.667
USD
Spread / Average Target
+1,381.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.50% | 31.68M | |
| +29.77% | 49.18B | |
| +1.00% | 42.11B | |
| +50.47% | 40.37B | |
| -5.26% | 28.85B | |
| +13.68% | 26.09B | |
| -22.99% | 18.71B | |
| +8.22% | 13.26B | |
| +32.41% | 12.32B | |
| -1.62% | 11.99B |
- Stock Market
- Equities
- DARE Stock
- News Daré Bioscience, Inc.
- Transcript : Daré Bioscience, Inc. - Shareholder/Analyst Call